Skip to main content

Advertisement

SpringerLink
Log in

Fluorine-18 Labeling of the HER2-Targeting Single-Domain Antibody 2Rs15d Using a Residualizing Label and Preclinical Evaluation

  • Research Article
  • Published:
Molecular Imaging and Biology Aims and scope Submit manuscript

Abstract

Purpose

Our previous studies with F-18-labeled anti-HER2 single-domain antibodies (sdAbs) utilized 5F7, which binds to the same epitope on HER2 as trastuzumab, complicating its use for positron emission tomography (PET) imaging of patients undergoing trastuzumab therapy. On the other hand, sdAb 2Rs15d binds to a different epitope on HER2 and thus might be a preferable vector for imaging in these patients. The aim of this study was to evaluate the tumor targeting of F-18 -labeled 2Rs15d in HER2-expressing breast carcinoma cells and xenografts.

Procedures

sdAb 2Rs15d was labeled with the residualizing labels N-succinimidyl 3-((4-(4-[18F]fluorobutyl)-1H-1,2,3-triazol-1-yl)methyl)-5-(guanidinomethyl)benzoate ([18F]RL-I) and N-succinimidyl 4-guanidinomethyl-3-[125I]iodobenzoate ([125I]SGMIB), and the purity and HER2-specific binding affinity and immunoreactivity were assessed after labeling. The biodistribution of I-125- and F-18-labeled 2Rs15d was determined in SCID mice bearing subcutaneous BT474M1 xenografts. MicroPET/x-ray computed tomograph (CT) imaging of [18F]RL-I-2Rs15d was performed in this model and compared to that of nonspecific sdAb [18F]RL-I-R3B23. MicroPET/CT imaging was also done in an intracranial HER2-positive breast cancer brain metastasis model after administration of 2Rs15d-, 5F7-, and R3B23-[18F]RL-I conjugates.

Results

[18F]RL-I was conjugated to 2Rs15d in 40.8 ± 9.1 % yield and with a radiochemical purity of 97–100 %. Its immunoreactive fraction (IRF) and affinity for HER2-specific binding were 79.2 ± 5.4 % and 7.1 ± 0.4 nM, respectively. [125I]SGMIB was conjugated to 2Rs15d in 58.4 ± 8.2 % yield and with a radiochemical purity of 95–99 %; its IRF and affinity for HER2-specific binding were 79.0 ± 12.9 % and 4.5 ± 0.8 nM, respectively. Internalized radioactivity in BT474M1 cells in vitro for [18F]RL-I-2Rs15d was 43.7 ± 3.6, 36.5 ± 2.6, and 21.7 ± 1.2 % of initially bound radioactivity at 1, 2, and 4 h, respectively, and was similar to that seen for [125I]SGMIB-2Rs15d. Uptake of [18F]RL-I-2Rs15d in subcutaneous xenografts was 16–20 %ID/g over 1–3 h. Subcutaneous tumor could be clearly delineated by microPET/CT imaging with [18F]RL-I-2Rs15d but not with [18F]RL-I-R3B23. Intracranial breast cancer brain metastases could be visualized after intravenous administration of both [18F]RL-I-2Rs15d and [18F]RL-I-5F7.

Conclusions

Although radiolabeled 2Rs15d conjugates exhibited lower tumor cell retention both in vitro and in vivo than that observed previously for 5F7, given that it binds to a different epitope on HER2 from those targeted by the clinically utilized HER2-targeted therapeutic antibodies trastuzumab and pertuzumab, F-18-labeled 2Rs15d has potential for assessing HER2 status by PET imaging after trastuzumab and/or pertuzumab therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1.
Fig. 2.
Fig. 3.
Fig. 4.
Fig. 5.
Fig. 6.

Similar content being viewed by others

References

  1. Schettini F, Buono G, Cardalesi C et al (2016) Hormone receptor/human epidermal growth factor receptor 2-positive breast cancer: where we are now and where we are going. Cancer Treat Rev 46:20–26

    Article  CAS  PubMed  Google Scholar 

  2. Santa-Maria CA, Nye L, Mutonga MB et al (2016) Management of metastatic HER2-positive breast cancer: where are we and where do we go from here? Oncology (Williston Park) 30:148–155

    Google Scholar 

  3. Recondo G Jr, de la Vega M, Galanternik F et al (2016) Novel approaches to target HER2-positive breast cancer: trastuzumab emtansine. Cancer Manag Res 8:57–65

    PubMed  PubMed Central  Google Scholar 

  4. Maximiano S, Magalhaes P, Guerreiro MP, Morgado M (2016) Trastuzumab in the treatment of breast cancer. BioDrugs 30:75–86

    Article  CAS  PubMed  Google Scholar 

  5. Gebhart G, Flamen P, De Vries EG et al (2016) Imaging diagnostic and therapeutic targets: human epidermal growth factor receptor 2. J Nucl Med 57(Suppl 1):81S–88S

    Article  CAS  PubMed  Google Scholar 

  6. Nitta H, Kelly BD, Allred C et al (2016) The assessment of HER2 status in breast cancer: the past, the present, and the future. Pathol Int 66:313–324

    Article  PubMed  Google Scholar 

  7. Karagoz Ozen DS, Ozturk MA, Aydin O et al (2014) Receptor expression discrepancy between primary and metastatic breast cancer lesions. Oncol Res Treat 37:622–626

    Article  PubMed  Google Scholar 

  8. Rack B, Zombirt E, Trapp E et al (2016) Comparison of HER2 expression in primary tumor and disseminated tumor cells in the bone marrow of breast cancer patients. Oncology 90:232–238

    Article  CAS  PubMed  Google Scholar 

  9. Kramer-Marek G, Oyen WJ (2016) Targeting the human epidermal growth factor receptors: imaging biomarkers from bench to bedside. J Nucl Med 57:996–1001

    Article  PubMed  Google Scholar 

  10. Sorensen J, Velikyan I, Sandberg D et al (2016) Measuring HER2-receptor expression in metastatic breast cancer using [68Ga]ABY-025 affibody PET/CT. Theranostics 6:262–271

    Article  PubMed  PubMed Central  Google Scholar 

  11. Mendler CT, Gehring T, Wester HJ et al (2015) 89Zr-labeled versus 124I-labeled αHER2 Fab with optimized plasma half-life for high-contrast tumor imaging in vivo. J Nucl Med 56:1112–1118

    Article  CAS  PubMed  Google Scholar 

  12. Ma T, Sun X, Cui L et al (2014) Molecular imaging reveals trastuzumab-induced epidermal growth factor receptor downregulation in vivo. J Nucl Med 55:1002–1007

    Article  CAS  PubMed  Google Scholar 

  13. Olafsen T, Sirk SJ, Olma S et al (2012) ImmunoPET using engineered antibody fragments: fluorine-18 labeled diabodies for same-day imaging. Tumour Biol 33:669–677

    Article  CAS  PubMed  Google Scholar 

  14. Olafsen T, Kenanova VE, Sundaresan G et al (2005) Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging. Cancer Res 65:5907–5916

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Kijanka M, Dorresteijn B, Oliveira S, van Bergen en Henegouwen PM (2015) Nanobody-based cancer therapy of solid tumors. Nanomedicine 10:161–174

    Article  CAS  PubMed  Google Scholar 

  16. De Meyer T, Muyldermans S, Depicker A (2014) Nanobody-based products as research and diagnostic tools. Trends Biotechnol 32:263–270

    Article  CAS  PubMed  Google Scholar 

  17. Keyaerts M, Xavier C, Heemskerk J et al (2016) Phase I study of 68Ga-HER2-nanobody for PET/CT assessment of HER2 expression in breast carcinoma. J Nucl Med 57:27–33

    Article  CAS  PubMed  Google Scholar 

  18. Xavier C, Blykers A, Vaneycken I et al (2016) 18F-nanobody for PET imaging of HER2 overexpressing tumors. Nucl Med Biol 43:247–252

    Article  CAS  PubMed  Google Scholar 

  19. Vaidyanathan G, McDougald D, Choi J et al (2016) Preclinical evaluation of 18F-labeled anti-HER2 nanobody conjugates for imaging HER2 receptor expression by immuno-PET. J Nucl Med 57:967–973

    Article  PubMed  PubMed Central  Google Scholar 

  20. Revets HM BC, Hoogenboom HM. (2011) Amino acid sequences directed against HER2 and polypeptides comprising the same for the treatment of cancers and/or tumors. US Patent 2011/0059090 Al

  21. Rockberg J, Schwenk JM, Uhlen M (2009) Discovery of epitopes for targeting the human epidermal growth factor receptor 2 (HER2) with antibodies. Mol Oncol 3:238–247

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Kramer-Marek G, Gijsen M, Kiesewetter DO et al (2012) Potential of PET to predict the response to trastuzumab treatment in an ErbB2-positive human xenograft tumor model. J Nucl Med 53:629–637

    Article  CAS  PubMed  Google Scholar 

  23. Vaneycken I, Devoogdt N, Van Gassen N et al (2011) Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer. FASEB J 25:2433–2446

    Article  CAS  PubMed  Google Scholar 

  24. Xavier C, Vaneycken I, D’Huyvetter M et al (2013) Synthesis, preclinical validation, dosimetry, and toxicity of 68Ga-NOTA-anti-HER2 nanobodies for iPET imaging of HER2 receptor expression in cancer. J Nucl Med 54:776–784

    Article  CAS  PubMed  Google Scholar 

  25. Vaidyanathan G, McDougald D, Choi J et al (2016) N-Succinimidyl 3-((4-(4-[18F]fluorobutyl)-1H-1,2,3-triazol-1-yl)methyl)-5-(guanidinomethyl)ben zoate ([18F]SFBTMGMB): a residualizing label for 18F-labeling of internalizing biomolecules. Org Biomol Chem 14:1261–1271

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Vaidyanathan G, Zalutsky MR (2007) Synthesis of N-succinimidyl 4-guanidinomethyl-3-[*I]iodobenzoate: a radio-iodination agent for labeling internalizing proteins and peptides. Nat Protoc 2:282–286

    Article  CAS  PubMed  Google Scholar 

  27. Pruszynski M, Koumarianou E, Vaidyanathan G et al (2013) Targeting breast carcinoma with radioiodinated anti-HER2 nanobody. Nucl Med Biol 40:52–59

    Article  CAS  PubMed  Google Scholar 

  28. Gray MA, Tao RN, DePorter SM et al (2016) A nanobody activation immunotherapeutic that selectively destroys HER2-positive breast cancer cells. Chembiochem 17:155–158

    Article  CAS  PubMed  Google Scholar 

  29. Lemaire M, D’Huyvetter M, Lahoutte T et al (2014) Imaging and radioimmunotherapy of multiple myeloma with anti-idiotypic nanobodies. Leukemia 28:444–447

    Article  CAS  PubMed  Google Scholar 

  30. Yu Z, Xia W, Wang HY et al (2006) Antitumor activity of an Ets protein, PEA3, in breast cancer cell lines MDA-MB-361DYT2 and BT474M1. Mol Carcinog 45:667–675

    Article  CAS  PubMed  Google Scholar 

  31. Choi J, Vaidyanathan G, Koumarianou E et al (2014) N-Succinimidyl guanidinomethyl iodobenzoate protein radiohalogenation agents: influence of isomeric substitution on radiolabeling and target cell residualization. Nucl Med Biol 41:802–812

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Lindmo T, Boven E, Cuttitta F et al (1984) Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Meth 72:77–89

    Article  CAS  Google Scholar 

  33. Kanojia D, Balyasnikova IV, Morshed RA et al (2015) Neural stem cells secreting anti-HER2 antibody improve survival in a preclinical model of HER2 overexpressing breast cancer brain metastases. Stem Cells 33:2985–2994

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Velikyan I, Wennborg A, Feldwisch J et al (2016) Good manufacturing practice production of [68Ga]Ga-ABY-025 for HER2 specific breast cancer imaging. Am J Nucl Med Mol Imaging 6:135–153

    PubMed  PubMed Central  Google Scholar 

  35. Trousil S, Hoppmann S, Nguyen QD et al (2014) Positron emission tomography imaging with 18F-labeled ZHER2:2891 affibody for detection of HER2 expression and pharmacodynamic response to HER2-modulating therapies. Clin Cancer Res 20:1632–1643

    Article  CAS  PubMed  Google Scholar 

  36. Pruszynski M, Koumarianou E, Vaidyanathan G et al (2014) Improved tumor targeting of anti-HER2 nanobody through N-succinimidyl 4-guanidinomethyl-3-iodobenzoate radiolabeling. J Nucl Med 55:650–656

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Sanchez-Crespo A (2013) Comparison of gallium-68 and fluorine-18 imaging characteristics in positron emission tomography. Appl Radiat Isot 76:55–62

    Article  CAS  PubMed  Google Scholar 

  38. D’Huyvetter M, Aerts A, Xavier C et al (2012) Development of 177Lu-nanobodies for radioimmunotherapy of HER2-positive breast cancer: evaluation of different bifunctional chelators. Contrast Media Mol Imaging 7:254–264

    Article  PubMed  Google Scholar 

  39. D’Huyvetter M, Vincke C, Xavier C et al (2014) Targeted radionuclide therapy with a 177Lu-labeled anti-HER2 nanobody. Theranostics 4:708–720

    Article  PubMed  PubMed Central  Google Scholar 

  40. Banappagari S, McCall A, Fontenot K et al (2013) Design, synthesis and characterization of peptidomimetic conjugate of BODIPY targeting HER2 protein extracellular domain. Eur J Med Chem 65:60–69

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Fuentes G, Scaltriti M, Baselga J, Verma CS (2011) Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silico based mechanism. Breast Cancer Res 13:R54

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Xu FJ, Yu YH, Bae DS et al (1997) Radioiodinated antibody targeting of the HER-2/neu oncoprotein. Nucl Med Biol 24:451–459

    Article  CAS  PubMed  Google Scholar 

  43. Langmuir VK, Mendonca HL, Woo DV (1992) Comparisons between two monoclonal antibodies that bind to the same antigen but have differing affinities: uptake kinetics and 125I-antibody therapy efficacy in multicell spheroids. Cancer Res 52:4728–4734

    CAS  PubMed  Google Scholar 

  44. Wargalla UC, Reisfeld RA (1989) Rate of internalization of an immunotoxin correlates with cytotoxic activity against human tumor cells. Proc Natl Acad Sci U S A 86:5146–5150

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Ward DM, Kaplan J (1990) The rate of internalization of different receptor-ligand complexes in alveolar macrophages is receptor-specific. Biochem J 270:369–374

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Stemmler HJ, Schmitt M, Harbeck N et al (2006) Application of intrathecal trastuzumab (Herceptin trademark) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer. Oncol Rep 15:1373–1377

    CAS  PubMed  Google Scholar 

  47. Stemmler HJ, Schmitt M, Willems A et al (2007) Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anti-Cancer Drugs 18:23–28

    Article  CAS  PubMed  Google Scholar 

  48. Dijkers EC, Oude Munnink TH, Kosterink JG et al (2010) Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther 87:586–592

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported in part by National Institutes of Health grants CA188177 and CA42324 and, for small-animal PET imaging, by S10RR31792. Excellent technical assistance of Elzbieta Krol (in vitro studies) and Xiao-guang Zhao (in vivo studies) is greatly appreciated. We also thank Thomas Hawk, Yulin Zhao, and Simone Degan for their excellent support with microPET/CT imaging studies.

Author information

Authors and Affiliations

  1. Department of Radiology, Duke University Medical Center, Box 3808, Durham, NC, USA

    Zhengyuan Zhou, Ganesan Vaidyanathan, Darryl McDougald, Choong Mo Kang & Michael R. Zalutsky

  2. The Feinberg School of Medicine, Northwestern University, Chicago, IL, 60611, USA

    Irina Balyasnikova

  3. In Vivo Cellular and Molecular Imaging Laboratory, Vrije Universiteit Brussel, 1090, Brussels, Belgium

    Nick Devoogdt

  4. Department of Chemistry, Colorado State University, Fort Collins, CO, 80523, USA

    Angeline N. Ta & Brian R. McNaughton

Authors
  1. Zhengyuan Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ganesan Vaidyanathan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Darryl McDougald
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Choong Mo Kang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Irina Balyasnikova
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Nick Devoogdt
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Angeline N. Ta
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Brian R. McNaughton
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Michael R. Zalutsky
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ganesan Vaidyanathan.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhou, Z., Vaidyanathan, G., McDougald, D. et al. Fluorine-18 Labeling of the HER2-Targeting Single-Domain Antibody 2Rs15d Using a Residualizing Label and Preclinical Evaluation. Mol Imaging Biol 19, 867–877 (2017). https://doi.org/10.1007/s11307-017-1082-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11307-017-1082-x

Key words

Search

Navigation